Type a ticker — we pressure-test it against live facts, filings, and sentiment.
CRISPR Therapeutics AG — Healthcare · Biotechnology carries a Plainview business-quality score of 5.5/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.
On the fundamentals, CRISPR Therapeutics AG shows trailing revenue of $4.1M, net cash of $1.78B, a loss per share of -5.49, valued at about 1263.9x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.